Gio Fidelito

Gio Fidelito

Auto-generated profile, based on publicly available information

Gio Fidelito

Department of Anatomy and Physiology, The University of Melbourne, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SZShan Zhang
Shan Zhang
BRBoris Reljić
Boris Reljić
CLChao Liang
Chao Liang
BKBaptiste Kerouanton
Baptiste Kerouanton
JFJoel Celio Francisco
Joel Celio Francisco
LHLena Ho
Lena Ho
The emergence of small open reading frame (sORF)-encoded peptides (SEPs) is rapidly expanding the known proteome at the lower end of the size distribution. Here, we show that the mitochondrial proteome, particularly the respiratory chain, is enriched for small proteins. Using a prediction and validation pipeline for SEPs, we report the discovery of 16 endogenous nuclear encoded, mitochondrial-localized SEPs (mito-SEPs). Through functional prediction, proteomics, metabolomics and metabolic flux modeling, we demonstrate that BRAWNIN, a 71 a.a. peptide encoded by C12orf73, is essential for respiratory chain complex III (CIII) assembly. In human cells, BRAWNIN is induced by the energy-sensing AMPK pathway, and its depletion impairs mitochondrial ATP production. In zebrafish, Brawnin deletion causes complete CIII loss, resulting in severe growth retardation, lactic acidosis and early death. Our findings demonstrate that BRAWNIN is essential for vertebrate oxidative phosphorylation. We propose that mito-SEPs are an untapped resource for essential regulators of oxidative metabolism.

23 January 2024 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
PMPaula M. Miotto
Paula M. Miotto
CYChieh-Hsin Yang
Chieh-Hsin Yang
SKStacey N. Keenan
Stacey N. Keenan
WNWilliam De Nardo
William De Nardo
CBCait A. Beddows
Cait A. Beddows
MWMatthew J. Watt
Matthew J. Watt

21 January 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
GFGio Fidelito
Gio Fidelito
MWMatthew J. Watt
Matthew J. Watt
RTRenea A. Taylor
Renea A. Taylor
Prostate cancer invokes major shifts in gene transcription and metabolic signaling to mediate alterations in nutrient acquisition and metabolic substrate selection when compared to normal tissues. Exploiting such metabolic reprogramming is proposed to enable the development of targeted therapies for prostate cancer, yet there are several challenges to overcome before this becomes a reality. Herein, we outline the role of several nutrients known to contribute to prostate tumorigenesis, including fatty acids, glucose, lactate and glutamine, and discuss the major factors contributing to variability in prostate cancer metabolism, including cellular heterogeneity, genetic drivers and mutations, as well as complexity in the tumor microenvironment. The review draws from original studies employing immortalized prostate cancer cells, as well as more complex experimental models, including animals and humans, that more accurately reflect the complexity of the in vivo tumor microenvironment. In synthesizing this information, we consider the feasibility and potential limitations of implementing metabolic therapies for prostate cancer management.

27 December 2022 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
GFGio Fidelito
Gio Fidelito
DAVID DE SOUZADAVID DE SOUZA
DAVID DE SOUZA
BNBirunthi Niranjan
Birunthi Niranjan
WNWilliam De Nardo
William De Nardo
SKShivakumar Keerthikumar
Shivakumar Keerthikumar
MWMatthew J. Watt
Matthew J. Watt
Cancer cells undergo metabolic reprogramming to meet increased bioenergetic demands. Studies in cells and mice have highlighted the importance of oxidative metabolism and lipogenesis in prostate cancer; however, the metabolic landscape of human prostate cancer remains unclear. To address this knowledge gap, we performed radiometric (14C) and stable (13C) isotope tracing assays in precision-cut slices of patient-derived xenografts (PDX). Glucose, glutamine, and fatty acid oxidation was variably upregulated in malignant PDXs compared with benign PDXs. De novo lipogenesis (DNL) and storage of free fatty acids into phospholipids and triacylglycerols were increased in malignant PDXs. There was no difference in substrate utilization between localized and metastatic PDXs and hierarchical clustering revealed marked metabolic heterogeneity across all PDXs. Mechanistically, glucose utilization was mediated by acetyl-CoA production rather than carboxylation of pyruvate, while glutamine entered the tricarboxylic acid cycle through transaminase reactions before being utilized via oxidative or reductive pathways. Blocking fatty acid uptake or fatty acid oxidation with pharmacologic inhibitors was sufficient to reduce cell viability in PDX-derived organoids, whereas blockade of DNL, or glucose or glutamine oxidation induced variable and limited therapeutic efficacy. These findings demonstrate that human prostate cancer, irrespective of disease stage, can effectively utilize all metabolic substrates, albeit with marked heterogeneity across tumors. We also confirm that fatty acid uptake and oxidation are targetable metabolic dependencies in human prostate cancer. Implications: Prostate cancer utilizes multiple substrates to fuel energy requirements, yet pharmacologic targeting of fatty acid uptake and oxidation reveals metabolic dependencies in localized and metastatic tumors.

1 December 2025 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PMPaula M. Miotto
Paula M. Miotto
JBJacqueline Bayliss
Jacqueline Bayliss
GFGio Fidelito
Gio Fidelito
JBJames R. Bell
James R. Bell
LDLea M. D. Delbridge
Lea M. D. Delbridge
MMMagdalene Montgomery
Magdalene Montgomery
Diabetic cardiomyopathy is a leading cause of death in patients with type 2 diabetes (T2D). Here, we show striking remodeling of cardiac protein secretion in mice with T2D, particularly an increase in the release of inner mitochondrial membrane proteins, which was associated with increased oxidative stress within the diabetic heart.

16 November 2025 in Journal of Lipid Research
Verified
Journal Article
Open access
SKStacey N. Keenan
Stacey N. Keenan
NSNatasha D. Suriani
Natasha D. Suriani
GFGio Fidelito
Gio Fidelito
JBJackie Bayliss
Jackie Bayliss
JLJieqiong Lou
Jieqiong Lou
MWMatthew J. Watt
Matthew J. Watt
Hydroxysteroid 17β dehydrogenase 11 (HSD17β11) is a member of the 17β-HSD family with canonical roles in steroid metabolism. Given its predominant localisation on lipid droplets, we investigated HSD17β11's role in lipid metabolism. In patients with metabolic dysfunction-associated fatty liver disease (MASLD), liver HSD17β11 levels are reduced, correlating with liver steatosis severity. HSD17β11 deletion in human cell lines increases lipid droplet size and number. This is associated with triglyceride accumulation due to impaired lipolysis and increased fatty acid uptake. Mechanistically, HSD17β11 facilitates the interaction between PLIN5 and ATGL, enabling efficient protein kinase A (PKA)-stimulated lipolysis. Surprisingly, Hsd17β11 deletion did not affect liver lipid metabolism or MASLD development in lean or obese mice. These findings demonstrate that while HSD17β11 is crucial for efficient PKA-mediated lipolysis in human cells, its deficiency appears redundant for lipid metabolism in mice.